Hospital Universitario Virgen Macarena -ko ikertzaileekin lankidetzan egindako argitalpenak (11)

2023

  1. Cardiovascular toxicity of checkpoint inhibitors: review of associated toxicity and design of the Spanish Immunotherapy Registry of Cardiovascular Toxicity

    Clinical and Translational Oncology, Vol. 25, Núm. 11, pp. 3073-3085

2022

  1. Erratum to “Takotsubo syndrome and cancer, clinical and prognostic implications, insights of RETAKO” [Med Clin (Barc). 2020;155(12):521-528] (Medicina Clinica (2020) 155(12) (521–528), (S0025775320301895), (10.1016/j.medcli.2020.01.033))

    Medicina Clinica

2021

  1. Stratification and management of cardiovascular risk in cancer patients. A consensus document of the SEC, FEC, SEOM, SEOR, SEHH, SEMG, AEEMT, AEEC, and AECC

    Revista Espanola de Cardiologia, Vol. 74, Núm. 5, pp. 438-448

2020

  1. Effectiveness of sacubitril–valsartan in cancer patients with heart failure

    ESC Heart Failure, Vol. 7, Núm. 2, pp. 763-767

  2. Takotsubo syndrome and cancer, clinical and prognostic implications, insights of RETAKO

    Medicina Clinica, Vol. 155, Núm. 12, pp. 521-528

2019

  1. Atrial Fibrillation in Active Cancer Patients: Expert Position Paper and Recommendations

    Revista Espanola de Cardiologia, Vol. 72, Núm. 9, pp. 749-759

  2. Replied to “Some remarks to SEOM clinical guidelines on cardiovascular toxicity (2018)”

    Clinical and Translational Oncology

  3. SEOM clinical guidelines on cardiovascular toxicity (2018)

    Clinical and Translational Oncology, Vol. 21, Núm. 1, pp. 94-105

2018

  1. Short- and Long-Term Prognostic Relevance of Cardiogenic Shock in Takotsubo Syndrome: Results From the RETAKO Registry

    JACC: Heart Failure, Vol. 6, Núm. 11, pp. 928-936

  2. Tako-tsubo Syndrome in Men: Rare, but With Poor Prognosis

    Revista Espanola de Cardiologia, Vol. 71, Núm. 9, pp. 703-708

2017

  1. Cardio-Onco-Hematology in Clinical Practice. Position Paper and Recommendations

    Revista Espanola de Cardiologia, Vol. 70, Núm. 6, pp. 474-486